http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H05239037-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5128cfc84a0fb189fceb3cd240c44493 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 |
| filingDate | 1992-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60b3e71383ede56b5b87a638cf708e90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d3deb462c1e86286cb27778fcd12f8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ad90146501893d02536fcf3f5670541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9381f55dc112019acef8d5d3d92bf37 |
| publicationDate | 1993-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H05239037-A |
| titleOfInvention | Serotonin Nervous system related therapeutic agent |
| abstract | (57) [Summary] [Structure] General formula [I] (Wherein, n 2-4 integer, R 1 represents a hydrogen atom or a methyl group, R 2 denotes a phenyl group which may have a substituent R 3. However, the substituents R 3 is 1-substituted alkyl-2-oxo-1,2-dihydroquinoxaline derivative represented by a halogen atom, a methyl group optionally substituted with a halogen atom, or a lower alkoxyl group) or a non-toxic salt thereof is used as an active ingredient. And a therapeutic agent for serotonin nervous system-related diseases. The compound [I] of the present invention and its hydrochloride salt are It has a strong affinity for the serotonin 1A receptor and is useful as an anxiolytic, antidepressant, blood pressure lowering agent, antiemetic agent (including anti-motion sickness agent, anti-space sickness agent, anti-vertigo agent, etc.) and the like. In addition, there are strong and weak affinities for the adrenergic α 1 receptor, depending on the cause and symptoms of the treatment target, An appropriate compound can be selected. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006137485-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8329694-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-5398984-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8524738-B2 |
| priorityDate | 1991-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.